Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 29 September 2015 | By Zachary Brennan
Late Monday evening, the House of Representatives cleared the final congressional hurdle for a bill that would compensate individuals who participate in clinical trials for rare diseases.
If signed by President Barack Obama, the legislation -- the Ensuring Access to Clinical Trials Act of 2015, which passed the Senate in July -- would enable those with rare diseases to receive compensation of up to $2,000 for participating in clinical trials without having the compensation be counted as income when calculating eligibility for Supplemental Security Income (SSI) and Medicaid.
The short, two-page bill would permanently allow this exclusion by making permanent the Improving Access to Clinical Trials Act of 2009, which is scheduled to expire in October.
If the bill is not signed into law, some people with rare diseases who receive SSI and Medicaid may end up not participating in clinical research because of the fear that the compensation received would make them ineligible to receive government medical benefits.
In a statement, the Cystic Fibrosis Foundation celebrated the House's passage of the bill, saying it will remove barriers for clinical trial participants with rare diseases, including cystic fibrosis.
In addition to the CF Foundation, 75 patient, industry, academic and medical organizations support the Ensuring Access to Clinical Trials Act, including the National Organization for Rare Disorders, the Muscular Dystrophy Association and the industry group Biotechnology Industry Organization.
The bill was introduced by Sens. Ron Wyden (D-OR), Orrin Hatch (R-UT), Sherrod Brown (D-OH) and Edward Markey (D-MA) in the Senate, and by Reps. Lloyd Doggett (D-TX), Tom Marino (R-PA) and James McGovern (D-MA) in the House.
Text of the Bill
Tags: clinical trials, House, Senate, clinical trials legislation
Regulatory Focus newsletters
All the biggest regulatory news and happenings.